NASDAQ
1.95USD
-0.08 (-3.94%)
We have scored 12 news catalysts on Autolus Therapeutics plc (AUTL) over the past 12 months. The biggest single-day move next to one of them came Oct 27, 2025, when AUTL closed +7.8%: “Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025”. Coverage across the window leans positive (average ticker sentiment +0.41). Most of the impact sits in sector healthcare and forward growth expectations.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
519M
P/E
—
EPS
—
Beta
2.09
52W range
1.175-2.58
Day range
1.93–2.05
Open
2.04
Prev close
2.03
Volume
1.4M
Avg volume
1.9M
Dividend
0.00
IPO
2018-06-22
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Autolus Therapeutics plc — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for AUTL: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Autolus Therapeutics plc is a clinical-stage biopharmaceutical entity primarily focused on pioneering T-cell-based immunotherapies for various oncological conditions. The company's pipeline includes several investigational programs: obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell therapy, is currently undergoing Phase 1b/2 trials for adult acute lymphoblastic leukemia (ALL). Additionally, AUTO1/22 is in a Phase 1 study for pediatric patients experiencing relapsed or refractory ALL. Autolus is also advancing AUTO4, a programmed T cell therapy designed to target TRBC1 for the treatment of peripheral T-cell lymphoma, and AUTO8, a product candidate currently in Phase I clinical trials for multiple myeloma. In earlier development, AUTO6NG, a programmed T cell therapy, is in preclinical research targeting GD2 for neuroblastoma, and AUTO5 is another hematological product candidate in its preclinical stages. Established in 2014, Autolus Therapeutics maintains its headquarters in London, United Kingdom.
